ClinicalTrials.gg
RecruitingNCT04020263LevoHeartShockUpdated Aug 5, 2025

Effect of Early Use of Levosimendan Versus Placebo on Top of a Conventional Strategy of Inotrope Use on a Combined Morbidity-mortality Endpoint in Patients With Cardiogenic Shock

A Phase 3 interventional study of Levosimendan 2.5 MG/ML Injectable Solution and Placebo in Cardiogenic Shock, sponsored by Pr Bruno LEVY. Recruiting at 28 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-05.

Sponsored by Pr Bruno LEVY · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jul 2023; still recruiting 3 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
610
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 62 studies in Shock, Cardiogenic with a site in France — 20 open to participants now, 21 under way, 2 of them phase 3. Shock, Cardiogenic · France.

Planned enrollment
Largest of 25
610 · median 164
Started
2023
with 5 others
Phase 3
6 of 62
2 open now
Primary completion
2027-02
later than 10 of 20 live
Registered
23rd of 62
by date

Among the 62 studies in Shock, Cardiogenic with a site in France, this one has the largest planned enrollment of the 25 interventional ones that give a count, is one of 6 that started in 2023, is one of 6 in phase 3, reaches primary completion later than 10 of the 20 other live ones, and was the 23rd registered.

Shock, Cardiogenic

297 studies on the registry are indexed under Shock, Cardiogenic; 134 are open to participants now.

Browse Shock, Cardiogenic studies →

Open to participants now

20 of the 62 studies in Shock, Cardiogenic with a site in France are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →

Who these studies take

Of the 101 Shock, Cardiogenic studies recruiting now, 70 (69%) set no upper age limit and 9 (9%) stop at 75 or younger; 11 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 62 studies in Shock, Cardiogenic with a site in France, or all of them as a file.
02

Study summary

Cardiogenic shock (CS) mortality remains high (40%). Despite their frequent use, few clinical outcome data are available to guide the initial selection of vasoactive drug therapies in patients with CS. Based on experts' opinions, the combination of norepinephrine-dobutamine is generally recommended as a first line strategy. Inotropic agents increase myocardial contractility, thereby increasing cardiac output. Dobutamine is commonly recommended to be the inotropic agent of choice and levosimendan is generally used following dobutamine failure. It may represent an ideal agent in cardiogenic shock, since it improves myocardial contractility without increasing cAMP or calcium concentration. At present, there are no convincing data to support a specific inotropic agent in patients with cardiogenic shock. Our hypothesis is that the early use of levosimendan, by enabling the discontinuation of dobutamine, would accelerate the resolution of signs of low cardiac output and facilitate myocardial recovery.

03

Conditions studied

  • Cardiogenic Shock

Keywords

  • heart failure
  • levosimendan
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Adult patient ≥ 18 years with cardiogenic shock defined by:

  • Adequate intravascular volume
  • Norepinephrine to maintain MAP at least at 65 mmHg for at least 3 hours and less than 24h. At inclusion the dose must be \<1 microgram/kg/min under norepinephrine base or \<2 microgram/kg/min under norepinephrine tartrate, OR/AND Dobutamine since at least 3h and less than 24h at inclusion.
  • Tissue hypoperfusion: at least 1 sign within 24h prior to inclusion (lactate ≥ 2 mmol/l; mottling, capillary refeel time > 3 seconds, oliguria \<500ml/24h or ≤ 20 ml/h during the last 2 hours, ScVO2 ≤ 60% or veno-arterial PCO2 gap ≥ 5 mmHg);

Exclusion criteria

Exclusion Criteria:

  • Myocardial sideration after cardiac arrest of non-cardiac etiology
  • Immediate or anticipated (within 6 hours) indication of Extra Corporel Life Support
  • Use of VA-ECMO or IMPELLA or LVAD;
  • Chronic renal failure requiring hemodialysis
  • Cardiotoxic poisoning
  • Septic cardiomyopathy
  • Previous levosimendan administration within 15 days
  • Cardiac arrest with non-shockable rhythm;
  • No flow time higher > 3 minutes;
  • Cardiac arrest with unknown no flow duration;
  • Total duration of cardiac arrest (no flow plus low flow) > 45 minutes;
  • Cerebral deficit with fixed dilated pupils
  • Patient moribund on the day of enrollment
  • Irreversible neurological pathology
  • Known to levosimendan or placebo, or one of its
  • Pregnant woman, birthing or breastfeeding mother
  • Minor (not emancipated)
  • Person deprived of liberty for judicial or administrative decision;
  • Adult subject to a legal protection measure (such as guardianship, conservatorship)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
610 participants (estimated)

Study arms

  • Experimental
    Levosimendan

    Experimental group: patients with cardiogenic shock treated with levosimendan in addition to the conventional strategy.

    Drug: Levosimendan 2.5 MG/ML Injectable Solution

  • Placebo comparator
    Placebo

    Control group: Patients with cardiogenic shock treated with placebo (Cernevit/Soluvit) in addition to the conventional strategy.

    Drug: Placebo

Interventions

  • DrugLevosimendan 2.5 MG/ML Injectable Solution

    Drug page: SimendanStudies of SimendanSimendan pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Levosimendan will be diluted with Glucose G5%. The reconstitution of levosimendan will be performed, as close as possible to the start of the infusion. A continuous infusion of levosimendan will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.

  • DrugPlacebo

    Placebo will be diluted with Glucose G5%. The reconstitution of Placebo will be performed, as close as possible to the start of the infusion. A continuous infusion of Placebo will be administered over 24 h without bolus, started at a rate of 0.1 μg per kilogram of body weight per minute and, in both the persistence of hypoperfusion signs and in the absence of rate-limiting side effects, will be increased after 2 to 4 hours to a maximum of 0.2 μg per kilogram per minute for a further 20 to 22 hours.

06

What researchers measure

Primary outcomes

  1. Proportion of All-cause mortality

    Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)

    Time frame: Day 30 following randomization

  2. Proportion of Extra Corporel Life Support implantation

    Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)

    Time frame: Day 30 following randomization

  3. Proportion of Dialysis

    Composite endpoint (i.e. All-cause Mortality and/or Extra Corporel Life Support implantation and/or dialysis)

    Time frame: Day 30 following randomization

Secondary outcomes

  1. Time to death

    Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).

    Time frame: Day 90

  2. Time to escalation to permanent left ventricular assist device or cardiac transplantation

    Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).

    Time frame: Day 90

  3. Time to dialysis

    Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).

    Time frame: Day 90

  4. Time to ECLS requirement

    Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).

    Time frame: Day 90

  5. number of cardiovascular events

    Prioritized composite endpoint with the following priority order: 1/ time to death, 2/ escalation to permanent left ventricular assist device or cardiac transplantation, 3/ dialysis, 4/ ECLS requirement, 5/ number of cardiovascular events (stroke, recurrent myocardial infarction, urgent coronary revascularization, re-hospitalization for heart failure).

    Time frame: Day 90

  6. Proportion of death.

    Time frame: Day 90

  7. Proportion of Extra Corporel Life Support implantation

    Time frame: Day 90

  8. Proportion of dialysis

    Time frame: Day 90

  9. Proportion of cardiac transplantation

    Time frame: Day 90

  10. Proportion of escalation to permanent Left Ventricular Assist Device

    Time frame: Day 90

  11. Proportion of stroke

    Time frame: Day 90

  12. Proportion of recurrent myocardial infarction

    Time frame: Day 90

  13. Proportion of urgent coronary revascularization

    Time frame: Day 90

  14. Proportion of re-hospitalization for heart failure

    Time frame: Day 90

  15. Proportion of All-cause mortality

    Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis on day 90.

    Time frame: Day 90

  16. Proportion of Extra Corporel Life Support implantation

    Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis on day 90.

    Time frame: Day 90

  17. Proportion of Dialysis

    Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis on day 90.

    Time frame: Day 90

  18. Number of dobutamine free days

    Time frame: From randomization to day 30

  19. Number of vasopressors free days

    Time frame: From randomization to day 30

  20. Number of ventilatory free days

    Time frame: From randomization to day 30

  21. Number of renal replacement free days

    Time frame: From randomization to day 90

  22. Lactate clearance

    Time frame: from randomization to day 7

  23. Duration of intensive care unit stay

    Time frame: Up to Intensive Care Unit discharge (assessed up to 1 month)

  24. Duration of hospitalization

    Time frame: Up to hospitalization discharge (assessed up to 1 month)

  25. Proportion of All-cause mortality

    Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis

    Time frame: days 7, 60, and 180 days and 12 months

  26. Proportion of Extra Corporel Life Support implantation

    Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis

    Time frame: days 7, 60, and 180 days and 12 months

  27. Proportion of dialysis

    Composite endpoint of all-cause mortality and/or ECLS requirement and/or dialysis

    Time frame: days 7, 60, and 180 days and 12 months

  28. Number of renal replacement free days

    Time frame: D 30, 60, 180 and at 12 months

  29. Proportion of death

    Time frame: days 180 and at 12 months

  30. Proportion of Extra Corporel Life Support implantation

    Time frame: days 180 and at 12 months

  31. Proportion of dialysis

    Time frame: days 180 and at 12 months

  32. proportion of cardiac transplantation

    Time frame: days 180 and at 12 months

  33. proportion of escalation to permanent left ventricular assist device

    Time frame: days 180 and at 12 months

  34. Proportion of stroke

    Time frame: days 180 and at 12 months

  35. Proportion of recurrent myocardial infarction

    Time frame: days 180 and at 12 months

  36. Proportion urgent coronary revascularization

    Time frame: days 180 and at 12 months

  37. proportion of re-hospitalization for heart failure

    Time frame: days 180 and at 12 months

  38. Occurrence of arrhythmias requiring therapy

    Occurrence of arrhythmias requiring therapy with anti-arrhythmic drugs or electric cardioversion (including atrial fibrillation, ventricular tachycardia, ventricular fibrillation, torsade de pointe)

    Time frame: from randomization to intensive care unit discharge.

  39. the changes in biomarkers

    From a dedicated biological collection on which we will measure existing and future biological parameters, we will evaluate the effect of Levosimendan on the changes in biomarkers between randomization and ICU/CCU discharge

    Time frame: from randomization to intensive care unit discharge.

  40. All-cause mortality and/or ECLS and/or dialysis

    From a dedicated biological collection on which we will measure existing and future biological parameters, we will evaluate the ability of clinical and biological measure to predict levosimendan effect for the primary endpoint.

    Time frame: Day 30

  41. All-cause mortality and/or ECLS and/or dialysis

    From a dedicated biological collection on which we will measure existing and future biological parameters, we will evaluate the ability of biological measure to predict subsequent outcome

    Time frame: At intensive care unit discharge

07

Study locations

24 of 28 sites recruiting
  • CHRU Strasbourg -Nouvel Hôpital Civil
    Strasbourg, Bas-Rhin 67091, France
    Recruiting
    • Ferhat MEZIANI, MD-PhD · Contact
    • Ferhat MEZIANI, MD-PhD · Principal investigator
  • AP-HM, Nord Hospital, Marseille
    Marseille, Bouches du Rhône 13015, France
    Recruiting
    • Laurent Bonello, MD · Contact
    • Laurent Bonello, MD · Principal investigator
  • CHU Caen
    Caen, Calvados 14000, France
    Not yet recruiting
    • Katrien Blanchart, MD · Contact
    • Katrien Blanchart, MD · Principal investigator
  • CHU Dijon
    Dijon, Côte d'Or 21000, France
    Recruiting
    • Jean-Pierre Quenot, MD-PhD · Contact
    • Jean-Pierre Quenot, MD-PhD · Principal investigator
  • CHU Besançon Jean Minjoz Hospital
    Besançon, Doubs 25000, France
    Recruiting
    • Hadrien WINISZEWSKI, MD · Contact
    • Hadrien WINISZEWSKI, MD · Principal investigator
  • CHU Nîmes, Carémeau Hospital
    Nîmes, Gard 30029, France
    Recruiting
    • Benoît Lattuca, MD · Contact
    • Benoît Lattuca, MD · Principal investigator
  • CHU Bordeaux - Hopital haut-leveque
    Bordeaux, Gironde 33600, France
    Recruiting
    • Edouard Gerbaud, MD · Contact
    • Edouard Gerbaud, MD · Principal investigator
  • CHU de Toulouse
    Toulouse, Haute-Garonne 31059, France
    Recruiting
    • Clément Delmas, MD · Contact
    • Clément Delmas, MD · Principal investigator
  • CHU Limoges, Dupuytren Hospital
    Limoges, Haute-Vienne 87000, France
    Recruiting
    • Philippe Vignon, MD · Contact
    • Philippe Vignon, MD · Principal investigator
  • CHU Montpellier, Arnaud de Villeneuve Hospital
    Montpellier, Hérault 34090, France
    Recruiting
    • François Roubille, MD · Contact
    • François Roubille, MD · Principal investigator
  • CHU Rennes, Pontchaillou Hospital
    Rennes, Ille et Vilaine 35000, France
    Recruiting
    • Abdelkader BAKHTI, MD · Contact
    • Abdelkader BAKHTI, MD · Principal investigator
  • CHU Grenoble, Michallon Hospital
    La Tronche, Isère 38043, France
    Recruiting
    • Joanna Bougnaud, MD · Contact
    • Joanna Bougnaud, MD · Principal investigator
  • CHU Nantes
    Nantes, Loire-Atlantique 44000, France
    Recruiting
    • Julien Plessis, MD · Contact
    • Julien Plessis, MD · Principal investigator
  • CHR Metz-Thionville, Mercy Hospital
    Ars-Laquenexy, Moselle 57245, France
    Recruiting
    • Guillaume Louis, MD · Contact
    • Guillaume Louis, MD · Principal investigator
  • CHRU Lille, Cœur Poumon Institute
    Lille, Nord 59000, France
    Recruiting
    • Gilles LEMESLE, MD-PhD · Contact
    • Gilles LEMESLE, MD-PhD · Principal investigator
  • APHP, La Pitié Salpêtrière (medical intensive care unit)
    Paris, Paris 75013, France
    Recruiting
    • Alain Combes, MD · Contact
    • Alain Combes, MD · Principal investigator
  • Hospices Civils de Lyon - Louis Pradel Hospital
    Bron, Rhône 69500, France
    Recruiting
  • APHP, Henri Mondor Hospital
    Créteil, Val de Marne 94010, France
    Recruiting
    • Raphaëlle HUGUET, MD · Contactraphaelle.huguet@aphp.fr · +33 1 49 81 21 11
    • Raphaelle HUGUET, MD · Principal investigator
  • CH Henri Duffaut, Avignon
    Avignon, Vaucluse 84000, France
    Not yet recruiting
    • Stéphane Andrieu, MD · Contact
    • Stéphane Andrieu, MD · Principal investigator
  • CHU Bordeaux
    Bordeaux, France
    Recruiting
    • Alexandre OUTARRA, MD-PhD · Contact
    • Alexandre OUTARRA, Md-PhD · Principal investigator
  • HENRI MONDOR -réanimation
    Créteil, France
    Not yet recruiting
    • Armand MEKONTSO DESSAP, MD-Phd · Contactarmand.dessap@aphp.fr · +33 1 49 81 21 11
    • Armand MEKONTSO DESSAP, MD-PhD · Principal investigator
  • Chu Dijon
    Dijon, France
    Recruiting
    • Pierre Grégoire GUINOT, MD-PhD · Contact
    • Pierre Grégoire GUINOT, MD-PhD · Principal investigator
  • CHU Grenoble -USIC
    La Tronche, 38700, France
    Recruiting
    • Nicolas PILIERO, MD · Contact
    • Nicolas PILIERO, MD · Principal investigator
  • AP-HM CHU la Timone
    Marseille, 13385, France
    Recruiting
    • Florent ARREGLE, MD · Contact
    • Florent ARREGLE, MD · Principal investigator
  • CHU Montpellier -hôpital Arnaud de Villeneuve
    Montpellier, 34295, France
    Recruiting
    • Philippe GAUDARD, MD-PhD · Contact
    • Philippe GAUDARD, MD-PhD · Principal investigator
  • Chu Rouen
    Rouen, France
    Recruiting
    • Emmanuel BESNIER, MD-PhD · Contact
    • Emmanuel BESNIER, MD-PhD · Principal investigator
  • HU Strasbourg USIC
    Strasbourg, France
    Not yet recruiting
  • CHRU Nancy
    Vandœuvre-lès-Nancy, France
    Recruiting
    • Bruno Lévy, Prof · Contact
    • Bruno LEVY, Prof · Principal investigator
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2023 (actual). Primary completion is estimated for Feb 2027, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 28, 2019
First posted
Jul 16, 2019
StartActual
Jul 3, 2023
Primary completionEst.
Feb 3, 2027
CompletionEst.
Jan 3, 2028
Last update
Aug 5, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 5, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04020263
Lead sponsor
Pr Bruno LEVY
Responsible party
Pr Bruno LEVY (Investigator coordonnator, Central Hospital, Nancy, France) — Sponsor-investigator
First posted
Jul 16, 2019
Start date
Jul 3, 2023
Primary completion
Feb 3, 2027 (estimated)
Completion
Jan 3, 2028 (estimated)
Last update
Aug 5, 2025

Study contacts

Bruno LEVY, Pr
Contact
b.levy@chru-nancy.fr
+33 3 83 15 40 84
Clément DELMAS, Dr
study chair · University Hospital, Toulouse
Nicolas GIRERD, Pr
study chair · CHRU Nancy
Patrick ROSSIGNOL, Pr
study chair · CHRU Nancy

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Simendan

Start the discussion